Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification

Detalles Bibliográficos
Autores principales: Zhao, Zhi-Mei, Wang, Song-Ping, Sun, Lei, Ji, You-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846480/
https://www.ncbi.nlm.nih.gov/pubmed/33186133
http://dx.doi.org/10.1097/CM9.0000000000001184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846480/
https://www.ncbi.nlm.nih.gov/pubmed/33186133
http://dx.doi.org/10.1097/CM9.0000000000001184

Ejemplares similares